Navigation Links
Pieris AG Enters into Anticalin Collaboration With Allergan, Inc.
Date:9/15/2009

FREISING-WEIHENSTEPHAN, Germany, September 15 /PRNewswire/ -- Pieris AG today announced that they have entered into a collaboration agreement with Allergan, Inc. (NYSE: AGN) that combines Pieris' proprietary Anticalin technology with Allergan's expertise in drug delivery and ophthalmic drug development with a goal of developing agents for the treatment of serious ocular disorders.

Under the terms of the collaboration Pieris will work with Allergan to optimize existing lead Anticalins and to design novel Anticalins. Allergan will be solely responsible for all discovery, development, and commercialization costs and will be responsible for clinical development and related activities and commercialization.

Pieris has granted Allergan a worldwide and exclusive license to Allergan for specific Anticalins to be used in the field and in return will receive an upfront payment of $10,000,000. Further financial terms were not disclosed.

Pieris is developing Anticalins for the treatment of a variety of disorders. Anticalins are a novel class of biologic drugs that are engineered to bind disease-relevant targets with high affinity and specificity. They are based on naturally occurring proteins called lipocalins, which are present in human plasma and body fluids where they function to bind, store and transport various small molecules including lipids and hormones.

Anticalins possess multiple distinguishing features, including an inherently high degree of stability, a property that lends itself to depot formulation strategies. Anticalins benefit from their small size (20kDa) and are produced in micro-organisms, thus conferring a significant cost advantage to the production of the therapeutic agent.

"Allergan has world class expertise in ophthalmology, and we look forward to working together to develop Anticalins as important medicines for the treatment of a number of ocular diseases. This collaboration further validates the potential for Anticalins as a new drug-class", said Claus Schalper, Interim-CEO of Pieris.

About Pieris AG

Pieris AG is an emerging biopharmaceutical company based in Freising, Germany focused on the discovery and advancement of Anticalins for the treatment of a variety of serious human diseases. The lead program PRS-050 is currently in late stage preclinical development for the indication oncology and will enter the clinic early next year. Founded in 2001, Pieris is funded by a number of international leading venture capital firms. For additional information, please visit the company's website, http://www.pieris-ag.com

For further information, please contact:

Dr. Birgit Zech, Director Business Development, Pieris AG, Phone: +49-8161-1411400


'/>"/>
SOURCE Pieris AG
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round
2. Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics
3. Dr M Group Selects Health Robotics Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia
4. Vita-Tech International, Inc. Donates One Ton of Vitamins To Polio Treatment Centers in Guinea, West Africa
5. SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company
6. New Jersey Surgery Centers Pick Health Informatics Consulting to Implement Patient Electronic Health Record Systems
7. DOE awards $377 million in funding for 46 energy frontier research centers
8. Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing
9. Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria
10. Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders
11. NEW Momentum(TM) Physician and Staff Scheduling Software for Imaging Centers, OB/GYN, and Other Specialty Practices Improves Productivity and Equity in Scheduling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... ... digital pathology, today announced their digital pathology technology has the potential to eliminate ... five medical centers in The Netherlands as part of the 2017 ISBI ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... flow controllers based on capillary thermal mass flow technology provide exponentially more accurate ... applications. Over 80% of all industrial processes—such as those involving chemical reactions, ...
(Date:4/27/2017)... a distinguished resource for research, development and commercialization of ... Thomas C. Seoh as President and CEO. Mr. Seoh ... becomes Executive Chairman and will continue to serve as ... Thomas Seoh commented, "I am excited and honored ... firm,s remarkable team of life science professionals, all of ...
(Date:4/26/2017)... ... April 26, 2017 , ... Baltimore bio ... MailGuardtm mail security screening solution at the National Postal Forum 2017 in Baltimore, ... a fast, highly accurate, easy to use and low cost threat detection solution ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
Breaking Biology News(10 mins):